No Data
No Data
Lilly Tops Morgan Stanley's Biopharma Pick List for 2025
Express News | Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared?
NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy
JonesTrading Maintains Intellia Therapeutics(NTLA.US) With Buy Rating, Maintains Target Price $40
Unlock the Full List